Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Candidiasis

Candidiasis

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Candidiasis

8 trials tracked for Candidiasis: 4 in phase 3 or 4.

8Trials tracked
4Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 2 Phase 1 1 Other / NA 1
  1. Phase 4 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Completed
  2. Phase 4 Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis Completed
  3. Phase 3 A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection Completed
  4. Phase 3 Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight Completed
  5. Phase 2 Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection Completed
  6. Phase 2 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women Completed
Show 2 more trials
  1. Phase 1 Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine Completed
  2. N/A Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Candidiasis prevalence of 13.46% and Cryptococcal meningitis of 3.15% among HIV-positive individuals
Infectious Disease Meta-analysis
Candidiasis prevalence of 13.46% and Cryptococcal meningitis of 3.15% among HIV-positive individuals New data shows prevalence of fungal infections in HIV patients
This meta-analysis evaluated the prevalence of opportunistic fungal infections in a population of HIV-positive individuals in Ethiopia. The …
New data reveals how common dangerous fungal infections like candidiasis and meningitis are among people living with HIV in Ethiopia.
NEJM Aug 22, 2026
Alpha-glucosidase inhibitors like acarbose show anti-virulence activity against Candida albicans in vitro
Infectious Disease Sys. Review
Alpha-glucosidase inhibitors like acarbose show anti-virulence activity against Candida albicans in vitro Could common diabetes drugs help stop fungal infections from building tough protective shields?
This systematic review evaluated alpha-glucosidase inhibitors, particularly acarbose, as selective antifungal inhibitors against Candida alb…
A common diabetes drug called acarbose may help break down the tough shields that hide dangerous fungal infections from treatment.
Frontiers Apr 14, 2026